. Author manuscript; available in PMC: 2024 Jul 1.

Published in final edited form as: Eur J Clin Invest. 2024 Feb 21;54(7):e14177. doi: 10.1111/eci.14177

TABLE 1.

Serum and tissue biochemistry

	RD Alb–Cc1^fl/fl	HFD Alb–Cc1^fl/fl	RD Alb+Cc1^fl/fl	HFD Alb+Cc1^fl/fl
Body Weight (g)	30.3 ± 0.6	40.6 ± 1.6^§	35.0 ± 1.3^*	49.2 ± 0.7^*§
% Liver/BW	4.4 ± 0.3	3.4 ± 0.2	4.5 ± 0.4	5.4 ± 0.2^*§
% WAT/BW	1.7 ± 0.2	5.6 ± 0.3^§	2.8 ± 0.1^*	7.5 ± 1.8^*§
NEFA (mEq/L)	0.5 ± 0.0	0.9 ± 0.1^§	0.7 ± 0.1^*	0.8 ± 0.1
Insulin (pmol/L)	31.6 ± 1.8	55.9 ± 6.1^§	45.5 ± 1.3^*	103.2 ± 9.4^*§
C-peptide (pmol/L)	370. ± 91.	521. ± 174^§	534. ± 187.	1246. ± 120^*§
C/I molar ratio	14.5 ± 1.5	9.5 ± 1.2^§	8.8 ± 1.2^*	11.3 ± 0.6
Triacylglycerol (mg/dL)	55.1 ± 7.2	56.6 ± 11.0	53.5 ± 6.4	78.1 ± 12.6
Hepatic TG (μg/mg)	65.2 ± 6.2	218.7 ± 41.5^§	97.8 ± 11.5^*	430.0 ± 90.1^*§

Male mice were fed HFD or kept on RD for 3 months starting at 5 months of age (n=5/genotype/feeding group). Mice were fasted from 5:00 p.m. until 11:00 a.m. the next morning before blood was drawn and tissues were excised. Except for blood glucose and tissues, values (mean±SEM) refer to serum levels.

P<0.5 Alb+Cc1^fl/fl vs Alb–Cc1^fl/fl per each feeding group;

^§

P<0.05 HFD vs RD/genotype, %WAT/BW denotes visceral adiposity; steady-state C/I molar ratio denotes C-peptide/Insulin molar ratio as a measure of basal insulin clearance; TG denotes triacylglycerol; hepatic TG was measured in μg/mg protein.